Cyclin dependent kinases as targets for cancer therapy

Update on Cancer Therapeutics

Volumn 1, Issue 3, 2006, Pages 311-332

  Shah, Manish A ^a   Schwartz, Gary K ^a  

^a Laboratory of New Drug Development   (United States)

Author keywords

Bryostatin; Cell cycle; Cyclin; Cyclin dependent kinases; Flavopiridol; Programmed cell death; Restriction point; UCN 01

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANTIDIARRHEAL AGENT; BRYOSTATIN; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CISPLATIN; COLCHICINE; CREATININE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; CYTOTOXIC AGENT; FLAVOPIRIDOL; FLUOROURACIL; GEMCITABINE; IMIDAZOPYRIDINE DERIVATIVE; INDISULAM; IRINOTECAN; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; OLOMOUCINE; PACLITAXEL; PD 0332991; PODOPHYLLOTOXIN; ROSCOVITINE; TAXANE DERIVATIVE; TOPOTECAN; UNCLASSIFIED DRUG; VINCA ALKALOID;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE MARROW SUPPRESSION; CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; CELL CYCLE; CELL CYCLE ARREST; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DNA DAMAGE; DNA REPAIR; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG TARGETING; DYSPNEA; ENZYME ACTIVATION; ENZYME INHIBITION; FATIGUE; FLUSHING; GASTROINTESTINAL TOXICITY; GENE OVEREXPRESSION; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOKALEMIA; HYPOTENSION; INJECTION SITE REACTION; INSULIN RESISTANCE; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMATITIS; THROMBOCYTOPENIA; TUMOR CELL; VOMITING;

EID: 33748577701     PISSN: 1872115X     EISSN: 1872115X     Source Type: Journal    
DOI: 10.1016/j.uct.2006.08.001     Document Type: Review

References (261)

1. Shah M.A., and Schwartz G.K. Cyclin-dependent kinases as targets for cancer therapy. Cancer Chemother Biol Response Modif 21 (2003) 145-170 [Annual 21]
2. Shah M.A., and Schwartz G.K. Cyclin-dependent kinases as targets for cancer therapy. Cancer Chemother Biol Response Modif 22 (2004) [Annual 21]
3. Sherr C.J., and Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13 12 (1999) 1501-1512
4. Grana X., and Reddy E.P. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 11 (1995) 211-219
5. Johnson D.G., and Walker C.L. Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol 39 (1999) 295-312
6. Kaldis P., Russo A.A., Chou H.S., Pavletich N.P., and Solomon M.J. Human and yeast cdk-activating kinases (CAKs) display distinct substrate specificities. Mol Biol Cell 9 9 (1998) 2545-2560
7. Pardee A.B. A restriction point control for normal animal cell proliferation. Proc Natl Acad Sci 71 (1974) 1286-1290
8. Malumbres M., and Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Cancer Rev 1 3 (2001) 222-231
9. Sherr C.J. The Pezcoller Lecture: cancer cell cycles revisited. Cancer Res 60 (2000) 3689-3695
10. Elledge S.J., and Harper J.W. The role of protein stability in the cell cycle and cancer. Biochim Biophys Acta 1377 (1998) M61-M70
11. Ford H.L., and Pardee A.B. The S-phase: beginning, middle, and end: a perspective. J Cell Biochem 30/31 Suppl. (1998) 1-7
12. Xu B., Kim S.-T., and Kastan M.B. Involvement of BRCA1 in S-phase and G2-phase checkpoints after ionizing radiation. Mol Cell Biol 21 (2001) 3445-3450
13. Zhou X., Wang X., Hu B., et al. An ATM-independent S phase checkpoint response involves Chk1 pathway. Cancer Res 62 (2002) 1598-1603
14. Ford H.L., and Pardee A.B. Cancer and the cell cycle. J Cell Biochem 32/33 Suppl. (1999) 166-172
15. d' Adda di Fagagna F.F., Reaper P.M., Clay-Farrace L., Fiegler H., Carr P., Von Zglinicki T., et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 426 6963 (2003) 194-198
16. Anderson S.S.L. Spindle assembly and the art of regulating microtubule dynamics by MAPs and stathmin/Op18. Trends Cell Biol 10 (2000) 261-267
17. Rudner A.D., and Murray A.W. The spindle assembly checkpoint. Curr Opin Cell Biol 8 (1996) 773-780
18. Nicklas R.B. How cells get the right chromosome. Science 275 (1997) 632-637
19. Salisbury J.L., Whitehead C.M., Lingle W.L., and Barrett S.L. Centrosomes and cancer. Biol Cell 91 (1999) 451-460
20. Blagden S.P., and Glover D.M. Polar expeditions - provisioning the centrosome for mitosis. Nat Cell Biol 5 6 (2003) 505-511
21. Glover D.M., Leibowitz M.H., McLean D.A., and Perry H. Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell 81 (1995) 95-105
22. Geit R., McLean D., Descamps S., Lee M.J., Raff J.W., Pringent C., et al. Drosophila Aurora A kinase is required to localize D-TACC to centrosomes and to regulate astral microtubules. J Biol Chem 156 3 (2002) 437-451
23. Reed J.C., and Bischoff J.R. Ringing chromosomes through cell division-and survivin' the experience. Cell 102 (2000) 545-548
24. Altieri D.C. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 7 (2001) 542-547
25. O'Connor D.S., Wall N.R., Porter A.C.G., and Altieri D.C. A p34cdc2 survival checkpoint in cancer. Cancer Cell 2 (2002) 43-54
26. Mistry P., Deacon K., Mistry S., et al. NF-kappa B promotes survival during mitotic cell cycle arrest. J Biol Chem (2003)
27. Karin M., and Lin A. NF-kB at the crossroad of Life and Death. Nat Immunol 3 (2002) 221-227
28. Palombella V.J., Rando O.J., Goldberg A.L., and Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 78 5 (1994) 773-785
29. Wang C.Y., Mayo M.W., and Baldwin A.S.J. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 274 5288 (1996) 784-787
30. Mayo M., and Balwin A.S. The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta 1472 2 (2000) M55-M62
31. Kerr J.F.R., Wyllie A.H., and Currie A.R. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer 26 (1972) 239-257
32. Reed J.C. Dysregulation of apoptosis in cancer. J Clin Oncol 117 9 (1999) 2941-2953
33. Martin S.J., and Green D.R. Protease activation during apoptosis. Death by a thousand cuts?. Cell 82 (1995) 349-352
34. Lazebnik Y.A., Takahashi A., Moir R.D., Goldman R.D., Poirier G.G., Kaufmann S.H., et al. Studies of the lamin proteinase reveal multiple parallel biochemical pathways during apoptotic execution. Proc Natl Acad Sci USA 92 (1995) 9042-9046
35. Kaufmann S.H., Desnoyers S., Ottaviano Y., Davidson N.E., and Poirier G.G. Specific proteolytic cleavage of poly (ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 53 (1993) 3976-3985
36. Lowe S.W., Ruley H.E., Jact T., and Housman D.E. p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74 (1993) 957-967
37. Eliopoulos A.G., Kerr D.J., Herod J., Hodgkins L., Krajewski S., Reed J.C., et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 11 (1995) 1217-1228
38. Ibardo A.M., Huang Y., Fang G., and Bhalla K. Bcl-xl overexpression inhibits taxol-induced yama protease activity and apoptosis. Cell Growth Differ 7 (1996) 1087-1094
39. Datta R., Manome Y., Taneja N., Boise L.H., Weichselbaum R., Thompson C.B., et al. Overexpression of Bcl-xl by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation. Cell Growth Differ 6 (1995) 363-370
40. Gajewski T.F., and Thompson C.B. Apoptosis meets signal transduction: elimination of a BAD influence. Cell 87 4 (1996) 589-592
41. Jarvis W.D., and Grant S. Protein kinase C targeting in antineoplastic treatment strategies. Invest New Drugs 17 3 (1999) 227-240
42. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 88 (1997) 323-331
43. El-Diery W.S., Harper J.W., O'Connor P.M., et al. Waf1/Cip1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54 (1994) 1169-1174
44. Chan T.A., Hwang P.M., Hermeking J., Kinzler K.W., and Vogelstein B. Cooperative effects of genes controling the G2/M checkpoint. Genes Dev 14 (2000) 1584-1588
45. Bunz F., Hwang P.M., Torrance C., Waldman T., Zhang Y., Dillehay L., et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104 3 (1999) 263-269
46. Yu J., Zhang L., Hwan P.M., et al. Identification and classification of p53-regulated genes. Proc Natl Acad Sci 96 (1999) 14517-14522
47. Clarke A.R., Gledhill S., Hooper M.L., et al. p53 Dependence of early apoptotic and proliferative responses within the mouse intestinal epithelium following gamma-irradiation. Oncogene 9 (1994) 1767-1773
48. Waldman T., Yongyang Y., Diollehay L., Yu J., Kinzler K.W., Vogelstein B., et al. Cell cycle arrest versus cell death in cancer therapy. Nat Med 3 (1997) 1034-1036
49. Hartwell L.H., and Kastan M.B. Cell cycle control and cancer. Science 266 (1994) 1821-1828
50. Harper J., and Elledge S.J. Cdk inhibitors in develpment and cancer. Curr Opin Genet Dev 6 (1996) 56-64
51. Shahjehan W.A., Laird P., and DeMeester T. DNA methylation: an alternative pathway to cancer. Ann Surg 234 (2001) 10-20
52. Sutherland R., and Musgrove E. Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Res 4 (2002) 14-17
53. Buckley M., Sweeney K.J., Hamilton J.A., et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene 8 (1993) 2127-2133
54. Chen Y.-N., Sharma S.K., Ramsey T.M., Jiang L., Martin M.S., Baker K., et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci 96 8 (1999) 4325-4329
55. Kobor M., and Greenblatt J. Regulation of transcription elongation by phosphorylation. Biochim Biophys Acta 13 (2002) 261-275
56. Oelgeschlager T. Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control. J Cell Physiol 190 (2002) 160-169
57. Deng L., Ammosova T., Pumfery A., et al. HIV-1 Tat interaction with RNA polymerase II C-terminal domain (CTD) and a dynamic association with CDK2 induce CTD phosphorylation and transcription from HIV-1 promoter. J Biol Cell 277 (2002) 33922-33929
58. Koumenis C., and Giaccia A. Transformed cell require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis. Mol Cell Biol 17 (1997) 7306-7316
59. Te Poele R., Okorokov A., and Joel S. RNA synthesis block by 5,6-dichloro-1-β-d-ribofuranosylbenzimidazole (DRB) triggers p53-dependent apoptosis in human colon carcinoma cells. Oncogene 18 (1999) 5765-5772
60. Senderowicz A.M. Cyclin-dependent kinases as targets for cancer therapy. In: Giaccone G., Schilsky R., and Sondel P. (Eds). Cancer chemotherapy and biological response modifiers, annual 20 (2002), Elsevier Science 169-188
61. Losiewicz M.D., Carlson B.A., Kaur G., Sausville E.A., and Worland P.J. Potent inhibition of cdc2 kinase activity by the flavonoid L86-8275. Biochem Biophys Biophys Res Commun 201 (1994) 589-595
62. Carlson B.A., Dubay M.M., Sausville E.A., Brizuela L., and Worland P.J. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase CDC2 and CDK4 in human breast carcinoma cells. Cancer Res 56 (1996) 2973-2978
63. Carlson B.A., Pearlstein R.A., Naik R.G., Sedlacek H.H., Sausville E.A., and Worland P.J. Inhibition of CDK2, CDK4 and CDK7 by flavopiridol and structural anologs. Proceedings of the American Association of Cancer Research (1996)
64. Dumant, JA, HMR Report No. B/98/0189/R, B/98/0188/R, 8/98/0187/R. HMR Oncology, 1996.
65. Cartee L., Wang Z., Decker R.H., Chellappan S.P., Fusaro G., Hirsch K.G., et al. The Cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI Expression while enhancing apoptosis in human myeloid leukemia cells. Cancer Res 61 6 (2001) 2583-2591
66. Konig A., Schwartz G.K., Mohammad R.M., et al. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia cell lines. Blood 90 (1997) 4307-4312
67. Motwani M., Jung C., Sirotnak F.M., She Y., Shah M.A., Gonen M., et al. Augmentation of apoptosis and tumor regressions by flavopiridol in the presence of CPT-11 in HCT116 colon cancer monolayers and xenografts. Clin Cancer Res 7 (2001) 4209-4219
68. Kitada S., Zapata J., Andreeff M., and Reed J.C. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 96 (2000) 393-397
69. Gao N., Dai Y., Rahmani M., Dent P., and Grant S. Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol. Mol Pharmacol 66 (2004) 956-963
70. Carlson B., Lahusen T., Singh S., Loaiza-Perez A., Worland P.J., Pestell R., et al. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res 59 18 (1999) 4634-4641
71. Wall N.R., O'Connor D.S., Plescia J., Pommier Y., and Altieri D.C. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 63 (2003) 230-235
72. Chao S.H., Fuginaga K., Marion J.E., Taube R., Sausville E.A., Senderowicz A.M., et al. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem 275 (2000) 28345-28348
73. Lam L., Pickeral O., Peng A., et al. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Bio 2 (2001) 1465-6914
74. Motwani M.V., Sirotnak F., She Y., Commes T., and Schwartz G.K. A novel target for modulating sensitivity to CPT-11 in colon cancer cells. Cancer Res 62 (2002) 3950-3955
75. Shah M.A., Kortmansky J., Motwani M., Drobjnak M., Gonen M., Yi S., et al. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin Cancer Res 11 10 (2005) 3836-3845
76. Bible K.C., and Kaufmann S.H. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res 56 21 (1996) 4856-4861
77. Schrump D.S., Mathews W., Chen G.A., et al. Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cell lines. Clin Cancer Res 4 (1998) 2885-2890
78. Drees M., Dengler W.A., Roth T., et al. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin Cancer Res 3 2 (1997) 271-279
79. Patel V., Senderowicz A.M., Pinto Jr. D., Igishi T., Raffeld M., Quintanilla-Martinez L., et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest 102 9 (1998) 1674-1681
80. Thomas J.P., Tutsch K.D., Cleary J.F., et al. Phase I clinical and pharmacokinetic trial of cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol 50 (2002) 465-472
81. Senderowicz A.M., Headlee D., Stinson S.F., et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 16 9 (1998) 2986-2999
82. Shapiro G.I., Patterson A., Lynch C., et al. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res 7 6 (2001) 1590-1599
83. Schwartz G.K., Ilson D., Saltz L., O'Reilly E., Tong W., Maslak P., et al. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 19 7 (2001) 1985-1992
84. Stadler W.M., Vogelzang N.J., Amato R., Sosman J., Taber D., Liebowitz D., et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium Study. J Clin Oncol 18 2 (2000) 371-375
85. Burdette-Radoux S., Tozer R.G., Lohmann R., et al. NCIC CTG phase II study of flavopiridol in patients with previously untreated metastatic malignant melanoma. Proc Am Soc Clin Oncol (2002)
86. Aklilu M., Kindler H.L., Donehower R.C., Mani S., and Vokes E.E. Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann Oncol 14 8 (2003) 1270-1273
87. Kouroukis C.T., Belch A., Crump M., et al. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21 9 (2003) 1740-1745
88. Lin T.S., Howard O.M., Neuberg D.S., et al. Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma. Leuk Lymphoma 43 4 (2002) 793-797
89. Flinn I.W., Byrd J.C., Bartlett N., Kipps T., Gribben J., et al. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res 29 11 (2005) 1253-1257
90. Tan A.R., Headlee D., Messmann R., Sausville E.A., Arbuck S., et al. A phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol 20 19 (2002) 4074-4082
91. Lin T., Dalton J.T., Wu B., et al. Flavopiridol given as a 30 minute intravenous (IV) bolus followed by 4-hr continous IV infusion results in clinical activity and tumor lysis in refractory chronic lymphocytic leukemia. Proc ASCO 23 (2004) 571 [abstract #6564]
92. Seynaeve C.M., Stetler-Stevenson M., Sebers S., Kaur G., Sausville E.A., and Worland P.J. Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res 53 9 (1993) 2081-2086
93. Akinaga S., Nomura K., Gomi K., and Okabe M. Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoind carcinoma, A431 cells. Cancer Chemother Pharmacol 33 4 (1994) 273-280
94. Kawakami K., Futami H., Takahara J., and Yamaguchi K. UCN-01, 7-hydroxylstaurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. Biochem Biophys Res Commun 219 3 (1996) 778-783
95. Akiyama T., Yoshida T., Tsujita T., Shimizu M., Mizukami T., Okabe M., et al. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as the induction of CDK inhibitor p21/CIP/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res 57 8 (1997) 1495-1501
96. Fan G., and Steer C.J. The retinoblastoma gene product is a negative modulator of the apoptotic pathway. Adv Enzyme Regul 36 (1996) 283-303
97. Hsueh C.T., Kelsen D., and Schwartz G.K. UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner. Clin Cancer Res 4 9 (1998) 2201-2206
98. Graves P.R., Yu L., Schwarz J.K., Gales J., Sausville E.A., O'Connor P.M., et al. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 275 8 (2000) 5600-5605
99. Busby E.C., Leistritz D.F., Abraham R.T., Karnitz L.M., and Sarkaria J.N. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res 60 8 (2000) 2108-2112
100. Yu Q., Rose J.H., Zhang H., et al. UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G2-M Checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. Cancer Res 62 (2002) 5743-5748
101. Sausville E.A., Arbuck S.G., Messmann R., Headlee D., Bauer K.S., Lush R.M., et al. Phase I trial of 72-hour continuous infusion of UCN-01 in patients with refractory neoplasms. J Clin Oncol 19 8 (2001) 2319-2333
102. Fuse E., Tanii H., Kurata N., et al. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res 58 (1998) 3248-3253
103. Sausville E.A., Lush R.D., Headlee D., Smith A.C., Figg W.D., Arbuck S.G., et al. Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models. Cancer Chemother Pharmacol 42 Suppl (1998) S54-S59
104. Tamura T., Sasaki Y., Minami H., et al. Phase I study of UCN-01 by 3 h infusion. Proc Am Soc Clin Oncol 18 (1999) 159a
105. Dees E.C., O'Reilly S., Figg W.D., et al. A phase I and pharmacologic study of UCN-01, a protein kinase C inhibitor. Proc Am Soc Clin Oncol 19 (2000) 205a
106. Kortmansky J., Shah M.A., Kaubisch A., Weyerbacher A., Yi S., et al. Phase I trial of the cyclin-dependent kinase inhibitor/protein kinase C inhibitor UCN-01 in combination with 5-FU in patients with advanced solid tumors. JCO 23 9 (2005) 1875-1884
107. Kondapaka S.B., Zarnowski M., Yver D.R., Sausville E.A., and Cushman S.W. 7-Hydroxystaurosporine (UCN-01) inhibition of Akt Thr308 but not Ser473 phosphorylation: a basis for decreased insulin-stimulated glucose transport. Clin Cancer Res 10 (2004) 7192-7198
108. Kraft A.S., Smith J.B., and Berkow R.L. Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60. Proc Natl Acad Sci 83 (1986) 1334-1338
109. Isakov N., Galron D., Mustelin T., Pettit G.R., and Altman A. Inhibition of phorbol ester-induced T cell proliferation by bryostatin is associated with rapid degradation of protein kinase C. J Immunol 150 4 (1993) 1195-1204
110. Lee H.W., Smith L., Pettit G.R., Vinitsky A., and Smith J.B. Ubiquitination of protein kinase C-alpha and degradation by the proteasome. J Biol Chem 271 (1996) 20973-20976
111. Asiedu C., Biggs J., Lilly M., and Kraft M. Inhibition of leukemic cell growth by the protein kinase C activator bryostatin-1 correlates with the dephosphorylation of cyclin-dependent kinase 2. Cancer Res 55 (1995) 3716-3720
112. Vrana J.A., Saunders A.M., Chellappan S.P., and Grant S. Divergent effects of bryostatin 1 and phorbol myristate acetate on cell cycle arrest and maturation in human myelomonocytic leukemia cells (U937). Differentiation 63 (1998) 33-42
113. Vrana J.A., Kramer L.B., Saunders A.M., Zhang X.F., Dent P., Povirk L.F., et al. Inhibition of protein kinase C activator-mediated induction of p21cip1 and p27kip1 by deoxycytidine analogs in human leukemia cells: relationship to apoptosis and differentiation. Biochem Pharmacol 58 (1999) 121-131
114. Koutcher J.A., Motwani M., Zakian K.L., Li X.L., Matei C., et al. The in vitro effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow. Clin Cancer Res 6 (2000) 1498-1507
115. Hickman P.F., Kemp G.J., Thompson C.H., Salisbury A.J., Wade K., Harris A.L., et al. Bryostatin 1, a novel antineoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: a 31P magnetic resonance spectroscopic study. Br J Cancer 72 (1995) 998-1003
116. Prendiville J., Crowther D., Thatcher N., Woll P.J., Fox B.W., McGown A., et al. A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer 68 (1993) 418-424
117. Philip P.A., Rea D., Thavasu P., Carmichael J., Stuart N.S., et al. Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee. J Natl Cancer Inst 85 (1993) 1812-1818
118. Jayson G.C., Crowther D., Prendiville J., McGown A., Scheid C., et al. A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24-hour intravenous infusion. Br J Cancer 72 (1995) 461-468
119. Varterasian M.L., Mohammad R.M., Eilender D.S., Hulburd K., Rodriguez D.H., Pemberton P.A., et al. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Clin Oncol 16 (1998) 56-62
120. Propper D.J., Macaulay V., O'Bryne K.J., Braybrooke J.P., Wilner S.M., Ganesan T.S., et al. A phase II study of bryostatin 1 in metastatic malignant melanoma. Br J Cancer 78 (1998) 1337-1341
121. Gonzalez R., Ebbinghaus S., Henthorn T.K., Miller D., and Kraft A.S. Treatment of patients with metastatic melanoma with bryostatin-1 - a phase II study. Melanoma Res 9 (1999) 599-606
122. Bedikian A.Y., Plager C., Stewart J.R., O'Brian C.A., Herdman S.K., Ross M., et al. Phase II evaluation of bryostatin-1 in metastatic melanoma. Melanoma Res 11 (2001) 183-188
123. Pfister D.G., McCaffrey J., Zahalsky A.J., et al. A phase II trial of bryostatin-1 in patients with metastatic or recurrent squamous cell carcinoma of the head and neck. Invest New Drugs 20 1 (2002) 123-127
124. Zonder J.A., Shields A.F., Zalupski M., Chaplen R., Heilbrun L.K., Arlauskas P., et al. A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer. Clin Cancer Res 7 (2001) 38-42
125. Winegarden J.D., Mauer A.M., Gajewsky T.F., et al. A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer. Lung Cancer 39 2 (2003) 191-196
126. Blackhall F.H., Ranson M., Radford J.A., Hancock B.W., Soukop M., McGown A.T., et al. A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma. Br J Cancer 84 (2001) 249-254
127. Brockstein B., Samuels B., Humerickhouse R., Arietta R., Fishkin P., Wade J., et al. Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer. Invest New Drugs 19 (2001) 249-254
128. Armstrong D.K., Blessing J.A., Look K.Y., Schilder R., and Nunez E.R. A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group Study. Invest New Drugs 21 3 (2003) 373-377
129. Armstrong D.K., Blessing J.A., Rader J., and Sorosky J.I. A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Invest New Drugs 21 4 (2003) 453-457
130. Clamp A.R., Blackhall F.H., Vasey P., et al. A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma. Br J Cancer 89 7 (2003) 52-54
131. Haas N.B., Smith M., Lewis N., et al. Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study. Clin Cancer Res 9 1 (2003) 109-114
132. Madhusudan S., Protheroe A., Propper D., et al. A multicenter phase II trial of bryostatin-1 in patients with advanced renal cancer. Br J Cancer 89 8 (2003) 1418-1422
133. Pagliaro L., Daliani D., Amato R., Tu S.M., Jones D., et al. A phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma. Cancer 89 (2000) 615-618
134. McClue S.J., Blake D., Clarke A.R., Cowan A., Cummings L., Fischer P.M., et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 102 5 (2002) 463-468
135. McClue S.J., Fischer P., Blake D., et al. Studies on the mechanism of action of CYC202 (R-roscovitine). Am Assoc Cancer Res (2002)
136. Vesely J., Havlicek L., Strnad M., Blow J.J., Donella-Deana A., Pinna L., et al. Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem 224 (1994) 771-786
137. Meijer L., Borgne A., Mulner O., Chong J.P., Blow J.J., Inagaki N., et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2, and cdk5. Eur J Biochem 243 (1997) 527-536
138. Alvi A., Gianella-Borradori A., Lane D., et al. A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-independent apoptosis in B-cell chronic lymphocytic leukemia by down-regulation of genes involved in transcription regulation and repair. Blood 102 11 (2003) 1587 [abstract]
139. Hahntow I., Schneller F., Oelsner M., et al. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia 18 (2004) 747-755
140. Kim E., Kim S., Shin D., et al. Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. Oncogene 23 (2004) 446-456
141. Maccallum D., Melville J., Watt K., et al. CYC202 (R-Roscovitine) induces apoptosis in multiple myeloma cells by down regulation of Mcl-1. Proc Am Assoc Cancer Res 45 (2004) 823 [abstract]
142. Maier A., Kelter G., Gianella-Borradori A., et al. Antitumor activity of CYC202, a cyclin-dependent kinase inhibitor, in human tumor xenografts in vitro. Am Assoc Cancer Res 44 (2003) 713 [abstract]
143. Whittaker S.R., Walton M.I., Garrett M.D., and Workman P. The cyclin-dependent kinase inhibitor CYC202 (R-Roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-activated protein kinase pathway. Cancer Res 64 (2004) 262-272
144. Benson C., Raynaud F., O'Donnell A., et al. Pharmacokinetics (PK) of the oral cyclin dependent kinase inhibitor CYC202 (R-roscovitine) in patients with cancer. Am Assoc Cancer Res 43 (2002) 273 [abstract]
145. White J.D., Cassidy J., Twelves C., et al. A phase I trial of oral cyclin dependent kinase inhibitor CYC202 in patients with advanced malignancy. Proc Am Soc Clin Oncol (2004) 3042 [abstract]
146. Pierga J.Y., Faivre S., Vera K., et al. A phase I and pharmacokinetic (PK) trial of CYC202, a novel oral cyclin-dependent kinase (CDK) inhibitor, in patients (pts) with advanced solid tumors. Proc Am Soc Clin Oncol 22 (2003) 210 [abstract 840]
147. Jones S.F., Burris H.A., Kies M., et al. A phase I study to determine the safety and pharmacokinetics (PK) of BMS-387032 given intravenously every three weeks in patients with metastatic refractory solid tumors. Am Soc Clin Oncol 22 (2003) 199 [abstract]
148. Shapiro G.I., Lewis N., Bai S., et al. A phase I study to determine the safety and pharmacokinetics (PK) of BMS-387032 with a 24-hour infusion given every three weeks in patients with metastatic refractory solid tumors. Am Soc Clin Oncol 22 (2003) 200 [abstract]
149. Byth K., Geh C., Forder C., et al. Novel cell cycle inhibitors: characterization in tumor cell lines and normal cycling cells. Am Assoc Cancer Res 44 (2003) 714 [abstract]
150. Cai D., Byth K., Shapiro G., et al. A novel CDK inhibitor induces cell cycle blockade, E2F-1 dependent apoptosis, and cytotoxic synergy with DNA damaging agents. Proc AACR 45 (2004) 190 [abstract #828]
151. Fukuoka K., Usuda J., Iwamoto Y., Fukumoto H., Nakamura T., Yoneda T., et al. Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells. Invest New Drugs 19 (2001) 219-227
152. Van Kesteren C., Beijnen J.H., and Schellens J.H. E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer. Anticancer Drugs 13 10 (2002) 989-997
153. Kesteren V., Mathot R.A.A., Raymond J.P., Armand J.P., Dittrich C., Dumez H., et al. Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation. J Clin Oncol 20 19 (2002) 4065-4073
154. Punt C.J.A., Fumoleau P., van de Walle B., Faber M.N., Ravic M., and Campone M. Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group. Ann Oncol 12 9 (2001) 1289-1293
155. Raymond E., ten Bokkel-Huinink W.W., Taieb J., Beijnen J.H., Faivre S., Wanders J., et al. Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a 1-hour infusion every three weeks in patietns with advanced cancer. J Clin Oncol 20 16 (2002) 3508-3521
156. Terret C., Zanetta S., Roche H., Schellens J.H., Faber M.N., Waners J., et al. A phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumors. Eur J Cancer 39 8 (2003) 1097-1104
157. Dittrich C., Dumez H., Calvert H., Hanauske A., Faber M.N., Wanders J., et al. Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors. Clin Cancer Res 9 14 (2003) 5195-5204
158. Haddad R.I., Shapiro G., Weinstein L., et al. A phase II study of E7070 in patients with metastatic, recurrent, or refractory head and neck squamous cell carcinoma (HNSCC): clinical activity and post-treatment modulation of Rb phosphorylation. Am Soc Clin Oncol 22 (2003) 201 [abstract]
159. Smyth J.F., Aamdal S., Awada A., Dittrich C., Caponigro F., Schoffski P., et al. Phase II study of E7070 in patients with metastatic melanoma. Ann Oncol 16 (2005) 158-161
160. Vanderwel S., Harvey P.J., Sheehan D.J., et al. Highly selective inhibition of CDK4 with pyrido[2,3-d]pyrimidine-7-ones. Proc AACR 45 (2004) 190 [abstract #828]
161. Booth J., Elliott W., Fry D.W., et al. Inhibition of Cdk4 causes tumor regression. Proc Am Assoc Cancer Res 45 (2004) 831 [abstract]
162. Fry D.W., Harvey P.J., Keller P.R., et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3 (2004) 1427-1438
163. Luria S.E., and Delbruck M. Mutations of bacteria from virus sensitivity to virus resistance. Genetics 28 (1943) 491
164. DeVita, VT. Principles of cancer management: chemotherapy. In: HS DeVita VT, Rosenberg SA, editors. Cancer: principles and practice of oncology. Lippincott-Raven Publishers: Philadelphia PA; 1997. p. 333-47.
165. Goldie J.H., and Coldman A.J. A model for tumor response to chemotherapy: an integration of the stem cell and somatic mutation hypotheses. Cancer Invest 3 6 (1985) 553-564
166. Goldie J.H., and Coldman A.J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63 11-12 (1979) 1727-1733
167. Shah M.A., and Schwartz G.K. Cell cycle mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 7 8 (2001) 2168-2181
168. Rowinsky E.K. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 48 (1997) 353-374
169. Schiff P.B., Fant J., and Horwitz S.B. Promotion of microtubule assembly in vitro by taxol. Nature 277 5698 (1979) 665-667
170. Schiff P.B., and Horwitz S.B. Taxol assembles tubulin in the absence of exogenous guanosine 5′-triphosphate or microtubule-associated proteins. Biochemistry 20 11 (1981) 3247-3252
171. Schiff P.B., and Horwitz S.B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77 3 (1980) 1561-1565
172. Yoo Y.D., Park J.K., Choi J.Y., Lee K.H., Kang Y.K., Kim C.S., et al. CDK4 down-regulation induced by paclitaxel is associated with G1 arrest in gastric cancer cells. Clin Cancer Res 4 12 (1998) 3063-3068
173. Long B.H., and Fairchild C.R. Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase. Cancer Res 54 16 (1994) 4355-4361
174. Brown T., Havlin K., Weiss G., Cagnola J., Koeller J., Kuhn J., et al. A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol 9 7 (1991) 1261-1267
175. Donaldson K.L., Goolsby G.L., Kiener P.A., and Wahl A.F. Activation of p34cdc2 coincident with taxol-induced apoptosis. Cell Growth Differ 5 10 (1994) 1041-1050
176. Ling Y.H., Yank Y., Consoli U., Tornos C., Andreeff M., and Perez-Soler R. Accumulation of cyclin B1, activation of cyclin B1-dependent kinase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with Taxol. Int J Cancer 75 (1998) 925-932
177. Clute P., and Pines J. Temporal and spatial control of cyclin B1 destruction in metaphase. Nat Cell Biol 1 (1999) 82-86
178. Yu D., Jing T., Liu B., Yau J., Tan M., McDonnel T.J., et al. Overexpression of ErbB2 blocks taxol-induced apoptosis by upregulation of p21Cip1 which inhibits p34Cdc2 kinase. Mol Cell 2 (1998) 581-591
179. Donaldson K.L., Goolsby G.L., and Wahl A.F. Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. Int J Cancer 57 6 (1994) 847-855
180. Blagosklonny M.V., Giannakakou P., el-Deiry W.S., Kingston D.G., Higgs P.I., Neckers L., et al. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res 57 1 (1997) 130-135
181. Chen C.Y., and Faller D.V. Phosphorylation of Bcl-2 protein and association with p21Ras in Ras-induced apoptosis. J Biol Chem 271 5 (1996) 2376-2379
182. Blagosklonny M.V., and Fojo T. Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer 83 2 (1999) 151-156
183. Trielli M.O., Andreassen P.R., Lacroix F.B., and Margolis R.L. Differential Taxol-dependent arrest of transformed and nontransformed cells in the G1 phase of the cell cycle, and specific related mortality of transformed cells. J Cell Biol 135 (1996) 689-700
184. Wang T.-H., Wang H.-S., and Soong Y.-K. Paclitaxel-Induced cell death. Cancer 88 (2000) 2619-2628
185. Motwani M., Delohery T.M., and Schwartz G.K. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res 5 7 (1999) 1876-1883
186. Kaubisch A., Kelsen D.P., Saltz L., Kemeny N., O'Reilly E., Ilson D., et al. A phase I trial of weekly sequential bryostatin (Bryo) and paclitaxel in patients with advanced solid tumors. Proc Am Soc Clin Oncol 18 (1999) 639 [abstract]
187. Bible K.C., and Kaufmann S.H. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res 57 (1997) 3375-3380
188. Wang S., Wang Z., Boise L., Dent P., and Grant S. Loss of the bcl-2 phosphorylation loop domain increases resistance of human leukemia cells (U937) to paclitaxel-mediated mitochondrial dysfunction and apoptosis. Biochem Biophys Res Commun 259 1 (1999) 67-72
189. Schmitt E., Cimoli G., Steyaert A., and Bertrand R. Bcl-xL modulates apoptosis induced by anticancer drugs and delays DEVDase and DNA fragmentation-promoting activities. Exp Cell Res 240 1 (1998) 107-121
190. Wang, S, Wang, Z, Boise, LH, Dent, P, G.S. Bryostatin-1 enhances paclitaxel induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xl. Leukemia 1999;13(10):1564-73.
191. Wang S., Guo C., Castillo A., Dent P., and Grant S. Effect of bryostatin-1 on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937). Biochem Pharmacol 56 5 (1998) 635-644
192. Schwartz G.K., O'Reilly E., Ilson D., Saltz L., Sharma S.K., Tong W., et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 20 8 (2001) 2157-2170
193. Wall M.E., Wani M.C., Cook C.E., et al. Plant anti-tumor agents 1. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminata. J Am Chem Soc 88 (1966) 3888-3890
194. Slichenmeyer W.J., Rowinsky E.K., Donehower R.C., and Kaufmann S.C. The current status of camptothecin analogues as antitumor agents. JNCI 85 (1993) 271-291
195. Li L.H., Fraser T.J., Olin E.J., and Bhuyan B.K. Action of camptothecin on mammalian cells in culture. Cancer Res 32 12 (1972) 2643-2650
196. Creemers C.J., Lund B., and Verwij J. Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat Rev 20 (1994) 73-96
197. Hsiang Y.-H., Hertzberg R., Hecht S., and Liu L.F. Camptothecin induces protein-linked DNA breaks via mammalian Topoisomerase I. J Biol Chem 260 (1985) 14873-14878
198. Hsiang Y.-H., Lihou M.G., and Liu F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptotheicin. Cancer Res 49 (1989) 5077-5082
199. Sane A.T., and Bertrand R. Caspase inhibition in camptothecin-treated U-937 cells is coupled with a shift from apoptosis to transient G1 arrest followed by necrotic cell death. Cancer Res 59 15 (1999) 3565-3569
200. Elias E., Lalun N., Lorenzato M., et al. Cell-cycle-dependent three-dimensional redistribution of nuclear proteins, P120, pKi-67, and SC 35 splicing factor, in the presence of topoisomerase I inhibitor camptothecin. Exp Cell Res 291 1 (2003) 176-188
201. Tsao Y.P., D'Apra P., and Liu L.F. The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B. Cancer Res 52 7 (1992) 1823-1829
202. Kohn E.A., Ruth N.D., Brown M.K., Linvingstone M., and Eastman A. Abrogation of the S phase DNA damage checkpoint results in S phase progression of premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation. J Biol Chem 277 29 (2002) 26553-26564
203. Falck J., Mailand N., Syljuasen R.G., Bartek J., and Lukas J. The ATM-Chk2-Cdc25A checkpoint pathway gaurds against radioresistant DNA synthesis. Nature 410 (2001) 842-847
204. Weller M., Winter S., Schmidt C., Esser P., Fontana A., Dichgans J., et al. Topisomerase-I inhibitors for human malignant glioma: differential modulation of p53, p21, bax, and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and beta-lapachone. Intl J Cancer 73 5 (1997) 707-714
205. Shimizu T., O'Connor P.M., Kohn K.W., and Pommier Y. Unscheduled activation of cyclin B1/cdc2 kinase in human promyelocytic leukemia cell line HL60 cells ungroing apoptosis induced by DNA damage. Cancer Res 55 (1995) 228-231
206. Saltz L.B., Kanowitz J., Kemeny N.E., Schaaf L., Spriggs D., Staton B.A., et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol 14 11 (1996) 2959-2967
207. Saltz L.B., Cox J.V., Blanke C., Rosen L.S., Fehrenbacher L., Moore M.J., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal carcinoma. Irinotecan Study Group. N Engl J Med 343 13 (2000) 905-912
208. Saijo N. Clinical trials of irinotecan hydrochloride (CPT, campto injection, topotecan injection) in Japan. Ann N Y Acad Sci 803 (1996) 292-305
209. Minderman H., Conroy J.M., O'Loughlin K.L., McQuaid D., Quinn P., et al. In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Ther 4 6 (2005) 885-900
210. Waldman T., Kinzler K.W., and Vogelstein B. P21 is necessary for the p53 mediated G1 arrest in human cancer cells. Cancer Res 55 (1995) 5187-5195
211. Shah, MA, Kortmansky, J, Gonen, M, Tse, A, Lefkowitz, R, Kelsen, D, et al. A phase I study of weekly irinotecan (CPT), cisplatin (CIS), and flavopiridol (F). 2004 Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2004;22(14S):4027.
212. Goldwasser F., Shimizu T., Jackman J., Hoki Y., O'Connor P.M., Kohn K.W., et al. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res 56 19 (1996) 4430-4437
213. Shao R.G., Cao C.X., Shimizu T., O'Connor P.M., Kohn K.W., and Pommier Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res 57 18 (1997) 4029-4035
214. Jones C.B., Clements M.K., Wasi S., and Daoud S.S. Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: abrogation of S/G2 arrest. Cancer Chemother Pharmacol 45 (2000) 252-258
215. Nieves-Neira W., and Pommier Y. Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI anticancer drugs screen: multifactorial relationships with topoisomerase I, protein kinase C, Bcl-2, p53, MDM-2, and caspace pathways. Int J Cancer 82 (1999) 396-404
216. Tse A., and Schwartz G.K. Abrogation of the G2/M checkpoint by 7-hydroxystaurosporine (UCN-01) on SN-38 treated cells: a strategy for targeting tumors with defective cell cycle checkpoints. Am Assoc Cancer Res (2002)
217. Bozko P., Larsen A.K., Raymond E., and Skladanowski A. Influence of G2 arrest on the cytotoxicity of DNA topoisomerase inhibitors toward human carcinoma cells with different p53 status. Acta Biochim Pol 49 1 (2002) 109-119
218. Allegra C.J., and Grem J.L. Antimetabolites. In: DeVita V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: principles and practice of oncology (1997), Lippincott-Raven, Philadelphia 432-452
219. Santi D.V., McHenry C.S., Raines R.T., and Ivanetich K.M. Kinetics and thermodynamics of the interaction of 5-fluoro-2′-deoxyuridylate with thymidylate synthase. Biochemistry 26 26 (1987) 8606-8613
220. van Triest B., Pinedo H.M., van Hensbergen Y., Smid K., Telleman F., Schoenmakers P.S., et al. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. Clin Cancer Res 5 3 (1999) 643-654
221. Grem J.L., Nguyen D., Monahan B.P., Kao V., and Geoffroy F.J. Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cells. Biochem Pharmacol 58 3 (1999) 477-486
222. Takeda H., Haisa M., Naomoto Y., Kawashima R., Satomoto K., Yamatuji T., et al. Effect of 5-fluorouracil on cell cycle regulatory proteins in human colon cancer cell line. Jpn J Cancer Res 90 6 (1999) 677-684
223. Farnham P.J., and Schimke R.T. Transcriptional regulation of mouse dihydrofolate reductase in the cell cycle. J Biol Chem 260 12 (1985) 7675-7680
224. Ayusawa D., Shimizu K., Koyama H., Kaneda S., Takeishi K., and Seno T. Cell-cycle-directed regulation of thymidylate synthase messenger RNA in human diploid fibroblasts stimulated to proliferate. J Mol Biol 190 4 (1986) 559-567
225. Kortmansky J., Shah M.A., Kemeny N., Kelsen D., Spriggs D., et al. A phase I/pharmacologic study of UCN-01 in combination with 5-fluorouracil in patients with advanced solid tumors. Proceedings of the NCI-EORTC Conference. Miami, FL (2001)
226. Sorenson C.M., and Eastman A. Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity: role of G2 arrest and DNA double strand breaks. Cancer Res 48 (1988) 4484-4488
227. Schlegel R., Belinsky G.S., and Harris M.O. Premature mitosis induced in mammalian cells by the protein kinase inhibitors 2-aminopurine and 6-dimethylaminopurine. Cell Growth Differ 1 4 (1990) 171-178
228. Demarcq C., Bunch R.T., Creswell D., and Eastman A. The role of cell cycle progression in cisplatin-induced apoptosis in Chinese hamster ovary cells. Cell Growth Differ 5 9 (1994) 983-993
229. Shi Y., Frankel A., Radvanyi L.G., Penn L.Z., Miller R.G., and Mills G.B. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res 55 9 (1995) 1982-1988
230. O'Dwyer P.J., Johnson S.W., and Hamilton T.C. Cisplatin and its analogues. In: DeVita V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: principles and practice of oncology (1997), Lippincott-Raven, Philadelphia 467-483
231. Barry M.A., Behnke C.A., and Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 40 10 (1990) 2353-2362
232. Judson P.L., Watson J.M., Gehrig P.A., Fowler W.C.J., and Haskill J.S. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy. Cancer Res 59 10 (1999) 2425-2432
233. Kaufmann W.K., and Paules R.S. DNA damage and cell cycle checkpoints. FASEB J 10 (1996) 238-247
234. Hawkins D.S., Demers G.W., and Galloway D.A. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56 (1996) 892-898
235. Brown R., Clugson C., Burns P., Edlin A., Vasey P., Vojtesek B., et al. Increased accumulation of p53 protein in cisplatin-resistant cell lines. Int J Cancer 55 (1993) 678-684
236. Perego P., Giarola M., Righetti S.C., Supino R., Caserini C., Delia D., et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56 (1996) 556-562
237. Zaffaroni N., Silvestrini R., Orlandi L., Bearzatto A., Gornati D., and Villa R. Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and -resistant human ovarian cancer cells. Br J Cancer 77 9 (1998) 1378-1385
238. Monks A., Harris E.D., Vaigro-Wolff A., Hose C.D., Connelly J.W., and Sausville E.A. UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines. Invest New Drugs 18 2 (2000) 95-107
239. Bunch R.T., and Eastman A. 7-Hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cells. Cell Growth Differ 8 7 (1997) 779-788
240. Husain A., Yan X.-Y., Rosales N., Schwartz G.K., and Spriggs D.R. UCN-01 enhances CDDP cytotoxicity in ovarian cancer cells independent of p53 gene status and abrogation of G2 block. Clin Cancer Res 4 (1997) 2089-2097
241. Sugiyama K., Shimizu M., Akiyama T., Tamaoki T., Yamaguchi K., Takahashi R., et al. UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation. Int J Cancer 85 5 (2000) 703-709
242. Huang P., and Plunkett W. Induction of apoptosis by gemcitabine. Semin Oncol 22 (1995) 19-25
243. Plunkett W., Huang P., Xu Y., Heinemann V., Grunewald R., and Gandhi V. Gemcitabine: metabolism, mechanisms of action and self-potentiation. Semin Oncol 22 4 Suppl. 11 (1995) 3-10
244. Huang P., Chubb S., Hertel L.W., Grindey G.B., and Plunkett W. Action of 2′2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51 (1991) 6110-6117
245. Cappella P., Tomasoni D., Faretta M., Lupi M., Montalenti F., Viale F., et al. Cell cycle effects of gemcitabine. Int J Cancer 93 (2001) 401-408
246. Huang P., and Plunkett W. Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 36 (1995) 181-188
247. Chen M., Hough A.M., and Lawrence T.S. The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization. Cancer Chemother Pharmacol 45 (2000) 369-374
248. Galmarini C.M., Clarke M.L., Falette N., Puisieux A., Mackey J.R., and Dumontet C. Expression of non-functional p53 affects the sensitivity of cancer cells to gemcitabine. Int J Cancer 97 (2002) 439-445
249. Jung C.P., Motwani M.V., and Schwartz G.K. Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin Cancer Res 7 (2001) 2527-2536
250. Ali S., El-Rayes B.F., Aranha O., Sarkar F.H., and Philip P.A. Sequence dependent potentiation of gemcitabine by flavopiridol in human breast cancer cells. Breast Cancer Res 90 1 (2005) 25-31
251. Zhou B.S., Tsai P., Ker R., Tsai J., Ho R., Yu J., et al. Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Clin Exp Metastasis 16 (1998) 43-49
252. Goan Y.G., Zhou B., Hu E., Mi S., and Yen Y. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in human KB cancer cell line. Cancer Res 59 (1999) 4204-4207
253. Matranga C.B., and Shapiro G.I. Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase. Cancer Res 62 (2002) 1707-1717
254. Banker D.E., Groudine M., Willman C.L., Norwood T., and Appelbaum F.R. Cell cycle perturbations in acute myeloid leukemia samples following in vitro exposures to therapeutic agents. Leuk Res 22 (1998) 221-239
255. Shi Z., Azuma A., Sampath D., Li Y.-X., Huang P., and Plunkett W. S-phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. Cancer Res 61 (2001) 1065-1072
256. Vankayalapati H., Bearss D.J., Saldanha J.W., Munoz R.M., Rojanala S., Von Hoff D.D., et al. Targeting aurora2 kinase in oncogenesis: a structural bioinformatics approach to target validation and rational drug design. Mol Cancer Ther 2 3 (2003) 283-294
257. Takahashi T., Sano B., Nagata T., Kato H., Sugiyama Y., Kunieda K., et al. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 94 2 (2003) 148-152
258. Hamada M., Yakushijin Y., Ohtsuka M., Kakimoto M., Yasukawa M., and Fujita S. Aurora2/BTAK/STK15 is involved in cell cycle checkpoint and cell survival of aggressive non-Hodgkin's lymphoma. Br J Haematol 121 (2003) 439-447
259. Nair J.S., Tse A., Keen N., and Schwartz G.K. A novel aurora B kinase inhibitor with potent anticancer activity either as a single agent or in combination with chemotherapy. Proc Am Soc Clin Oncol 45 (2004) 848 [abstract 9568]
260. Harrington E.A., Bebbington D., Moore J., Rasmussen R.K., Ajose-Adeogun A.O., Nakayama T., et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med (2004) 262-267
261. Solit D.B., She Y., Moasser M.M., et al. Pulsatile administration of the EGF receptor inhibitor Iressa (ZD1839) is significantly more effective than continuous dosing for sensitizing tumors to taxol. Am Assoc Cancer Res 44 2 (2003) LB-5